About the Program
The Patient Rebate Program for ZOSTAVAX is available for privately insured patients vaccinated between January 1, 2014 and December 31, 2014.
Although the Patient Rebate Program for ZOSTAVAX expired on December 31, 2014, Merck will continue to process rebate submissions for qualifying doses administered on or before December 31, 2014 in accordance with the 2014 Terms and Conditions.
If you have questions, please call 1-888-ZOSTA-INFO.
ZOSTAVAX is a vaccine that is used for adults 50 years of age or older to prevent Shingles (also known as zoster).
Important Safety Information
- ZOSTAVAX does not protect everyone, so some people who get the vaccine may still get Shingles.
- You should not get ZOSTAVAX if you are allergic to any of its ingredients, including gelatin or neomycin, have a weakened immune system, take high doses of steroids, or are pregnant or plan to become pregnant. You should not get ZOSTAVAX to prevent chickenpox.
- Talk to your health care provider if you plan to get ZOSTAVAX at the same time as PNEUMOVAX®23 (Pneumococcal Vaccine Polyvalent) because it may be better to get these vaccines at least 4 weeks apart.
- Possible side effects include redness, pain, itching, swelling, hard lump, warmth, or bruising at the injection site, as well as headache.
- ZOSTAVAX contains a weakened chickenpox virus. Tell your health care provider if you will be in close contact with newborn infants, someone who may be pregnant and has not had chickenpox or been vaccinated against chickenpox, or someone who has problems with their immune system. Your health care provider can tell you what situations you may need to avoid.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or
Please read the accompanying Patient Information for ZOSTAVAX® (Zoster Vaccine Live) and discuss it with your doctor. The physician
Prescribing Information also is available.
Back to top